They are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing their patented piezo-print technology to deliver micro-doses of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye.
January 25, 2018
Ladenburg Thalmann, Roth Capital Partners
To view the prospectus for Eyenovia, Inc. IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277